{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:37Z","timestamp":1790949157395,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00520-019-04988-7","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T10:02:56Z","timestamp":1564135376000},"page":"1855-1865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"Ferdinand","family":"Haslbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Safanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoaneta","family":"Tomova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Porubska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Bajory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Bjorklof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Kalinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"4988_CR1","volume-title":"Textbook of bone metastases","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Brown JE (2005) Monitoring response to treatment\u2014the role of biochemical markers. In: Jasmin C, Coleman RE, Coia LR, Capanna R, Saillant G (eds) Textbook of bone metastases. John Wiley & Sons Ltd., Chichester, UK"},{"issue":"Suppl 4","key":"4988_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14\u201327","journal-title":"Oncologist"},{"key":"4988_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","volume":"9","author":"CL Vogel","year":"2004","unstructured":"Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9:687\u2013695","journal-title":"Oncologist"},{"key":"4988_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579\u2013584","journal-title":"Ann Oncol"},{"key":"4988_CR5","volume-title":"Book Xgeva summary of product characteristics","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency (2018) Xgeva summary of product characteristics. In: Book Xgeva summary of product characteristics. European Medicines Agency, City"},{"key":"4988_CR6","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"4988_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"4988_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3111\/13696998.2016.1150852","volume":"19","author":"J Pereira","year":"2016","unstructured":"Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R (2016) Cost of skeletal complications from bone metastases in six European countries. J Med Econ 19:611\u2013618","journal-title":"J Med Econ"},{"key":"4988_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"4988_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"4988_CR11","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04988-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:17:45Z","timestamp":1595632665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04988-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4988"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04988-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,26]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study complied with all relevant national requirements on a country-by-country basis. Written informed consent was obtained from the patient or legally acceptable representative. National ethics committee approval of the protocol and informed consent form was obtained before recruitment of patients or any data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ferdinand Haslbauer, Martin Safanda, Antoaneta Tomova, Zolt\u00e1n Bajory, Miriam Porubska, and Dmitry Kalinin have no conflicts of interest to declare. Andreas Petzer declares to hold a non-remunerative position of influence as advisory board member of Amgen and has received speaker honoraria of Amgen. Richard Greil has received research grants from Celgene, Merck, Roche, Takeda, AstraZeneca, Novartis, Amgen and BMS, and consulting fees from Celgene, Roche, BMS, Takeda, Abbvie, AstraZeneca, and Novartis. Christine Jaeger, Katja Bjorklof, and Daniela Niepel are employees of Amgen and hold Amgen stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}